Vitamin C for Preventing and Treating the Common Cold

The role of vitamin C in the prevention and treatment of the common cold has been a subject of controversy for at least 60 years. Public interest in the subject, stimulated originally by the vigorous advocacy of Nobel laureate Linus Pauling during the 1970s [1], continues to be high. We have recently updated the Cochrane Review [2] on this topic (Text S1), incorporating 55 comparative studies that have been carried out over a period of 65 years.

The Updated Review
We sought to discover whether vitamin C in doses of 200 mg or more daily (Figure 1) reduces the incidence, duration, or severity of the common cold when used either as continuous prophylaxis or after the onset of cold symptoms. Criteria for inclusion were placebo-controlled trials to prevent or treat the common cold using oral doses of vitamin C of 200 mg/day or more. Literature from 1940 to 2004 was methodically screened.

An overview of the results of the three meta-analyses is shown in Table 1. Incidence was not altered in the subgroup of 23 community studies where prophylactic doses as high as 2 g daily were used. But a subgroup of six studies of marathon runners, skiers, and soldiers exposed to significant cold and/or physical stress experienced, on average, 50% reduction in common cold incidence.

Duration of cold episodes that occurred during prophylaxis was significantly reduced in both children and adults. For children this represented an average reduction of 14% in symptom days, while in adults the reduction was 8%.

For the seven trials that evaluated the therapeutic impact of vitamin C used at the onset of symptoms (all in adults), benefits were not observed for duration of episodes, although one of the large trials recorded a statistically significant reduction in the duration of colds among participants administered a single vitamin C dose of 8 g on the day of symptom onset [3].

Implications of the Review
The lack of effect of prophylactic vitamin C supplementation on the incidence of common cold in normal populations throws doubt on the utility of this wide practice. The clinical significance of the minor reduction in duration of common cold episodes experienced during prophylaxis is questionable, although the consistency of these findings points to a genuine biological effect.

In special circumstances, where people used prophylaxis prior to extreme physical exertion and/or exposure to significant cold stress, the collective evidence indicates that vitamin C supplementation may have a considerable beneficial effect; it was the results of one of these six trials, with schoolchildren in a skiing school [4], that particularly impressed Pauling [1]. However, great caution should be exercised in generalizing from this finding, which is based mainly on marathon runners.

No benefits have been observed from therapeutic use of doses totalling 10 g that was divided for the first three days of illness. The equivocal findings of the large study, which used 8 g only on the day of onset of respiratory symptoms [3], are tantalising and deserve further assessment.

None of the therapeutic trials carried out so far has examined the effect of vitamin C on children, even though the prophylaxis trials have shown substantially greater effect on episode duration in children.

Study quality for the trials included in these three meta-analyses was


Copyright: © 2005 Douglas and Hemilä. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Robert M. Douglas is at the National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia. Harri Hemilä is at the Department of Public Health, University of Helsinki, Finland.

Competing Interests: RMD was an organising author of one of the papers considered in the review. HH declares that he has no competing interests.

*To whom correspondence should be addressed. E-mail: bobdouglas@netspeed.com.au

DOI: 10.1371/journal.pmed.0020168

The Best Practice section summarizes the current evidence on an important health intervention.
variable, but sensitivity analysis, where we excluded studies from the analysis that were less adequately blinded or randomized, did not change the general conclusions of the Cochrane Review.

Future work on this topic should explore the value of high dose therapy—in particular, in children—and the mechanisms underlying the observed prophylaxis benefits in those exposed to substantial physical and/or cold stress.

Text S1. Updated Cochrane Review


These meta-analyses were of placebo-controlled trials that provided data on incidence and duration of respiratory episodes during continuous oral prophylaxis, or on duration of respiratory episodes following therapy at onset of colds using doses in excess of 200 mg of vitamin C. Prophylaxis indicates vitamin C supplementation over the entire study period. All combined results were pooled using the random effects model.

Heterogeneity between trial outcomes in the group: the $\chi^2$ test for heterogeneity with $p > 0.05$ indicates lack of heterogeneity, and the I$^2$ test with I$^2 = 0\%$ indicates no evidence of heterogeneity, with 100% being the maximum in the I$^2$ scale [5].

CI, confidence interval; RED, relative effect on duration of colds (e.g., if a seven-day cold is shortened by one day, that corresponds to RED = −14% = −1/7); RR, relative risk of colds.

Table 1: Results of the Three Meta-Analyses

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Subgroup</th>
<th>Number of Trials</th>
<th>Number of Participants</th>
<th>Test of Heterogeneity *</th>
<th>Magnitude of the Vitamin C Effect (95% CI) b</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Incidence of colds during prophylaxis</td>
<td>General community studies</td>
<td>29</td>
<td>11,077</td>
<td>$\rho = 0.02, I^2 = 38%$</td>
<td>RR = 0.96 (0.92, 1.00)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$\rho = 0.7, I^2 = 0%$</td>
<td>RR = 0.98 (0.95, 1.00)</td>
</tr>
<tr>
<td></td>
<td>Short-term exposure to cold and/or severe physical stress</td>
<td>6</td>
<td>642</td>
<td>$\rho = 0.9, I^2 = 0%$</td>
<td>RR = 0.50 (0.38, 0.66) c</td>
</tr>
<tr>
<td>2. Duration of colds during prophylaxis</td>
<td>Children</td>
<td>12</td>
<td>2,434</td>
<td>$\rho = 0.30, I^2 = 15%$</td>
<td>RED = −13.6% (−21.6%, −5.6%) c</td>
</tr>
<tr>
<td></td>
<td>Adults</td>
<td>18</td>
<td>7,242</td>
<td>$\rho = 0.19, I^2 = 22%$</td>
<td>RED = −8.0% (−13.1%, −3.0%) d</td>
</tr>
<tr>
<td>3. Duration of colds treated at the onset of symptoms</td>
<td>Adults only</td>
<td>7</td>
<td>3,294</td>
<td>$\rho = 0.11, I^2 = 42%$</td>
<td>RED = −2.5% (−10.1%, +5.0%)</td>
</tr>
</tbody>
</table>

a Heterogeneity between trial outcomes in the group: the $\chi^2$ test for heterogeneity with $p > 0.05$ indicates lack of heterogeneity, and the I$^2$ test with I$^2 = 0\%$ indicates no evidence of heterogeneity, with 100% being the maximum in the I$^2$ scale [5].

b CI, confidence interval; RED, relative effect on duration of colds (e.g., if a seven-day cold is shortened by one day, that corresponds to RED = −14% = −1/7); RR, relative risk of colds.

c Statistically significant benefit favours those receiving vitamin C with $p < 0.0001$.
d Statistically significant benefit favours those receiving vitamin C with $p < 0.002$.

References